HIF1A and central nervous system cancer: The presence of this mutation in glioma upregulates HIF-1a expression, which decreases c-MYC activity, resulting in a consequential decline in miR-20a, is responsible for glioma cell proliferation and resistance to temozolomide (TMZ) treatment.63